

2024年12月1日世界艾滋病日

社会共治 终结艾滋 共享健康

TAKE THE RIGHTS PATH



国家卫生健康委员会
国家疾病预防控制中心
国务院防治艾滋病工作委员会办公室

中国标准连续出版物号: CN11-5457/R

邮发代号: 24-81

国内定价: 25.00元



ISSN 1673-5234
CN 11-5457/R

中国病原生物学杂志

ZHONGGUO BINGYUAN SHENGWUXUE ZAZHI

2025年2月第20卷第2期

(总第218期)

Feb. 2025 Vol. 20, No. 2

国家疾病预防控制局 主管
中华预防医学会 主办
山东省寄生虫病防治研究所



JOURNAL OF PATHOGEN BIOLOGY

中国病原生物学杂志

二〇二五年二月

第二十卷

第二期

中华预防医学会系列杂志

中文核心期刊(基础医学类)
中国科学引文数据库(CSCD)来源期刊
中国科技核心期刊
中国生物医学类核心期刊
RCCSE中国核心学术期刊
科技期刊世界影响力指数(WJCI)报告收录期刊
中国科技论文统计源期刊
《中国学术期刊综合评价数据库》来源期刊
《中国核心期刊(遴选)数据库》收录期刊

ISSN 1673-5234



02>

中华预防医学会系列杂志
SERIAL JOURNAL OF CHINESE PREVENTIVE MEDICINE ASSOCIATION

2 2025

2024.12.1

世界艾滋病日

社会共治 终结艾滋 共享健康

TAKE THE RIGHTS PATH

国家卫生健康委员会
国家疾病预防控制中心
国务院防治艾滋病工作委员会办公室



review of the worldwide situation and the WHO/IUATLD global surveillance project. international union against tuberculosis and lung disease[J]. Clin Infect Dis,2017,24(S1):121-130.

[7] Sandman L, Schluger NW, Davidow AL, et al. Risk factors for rifampin- monoresistant tuberculosis; A case-control study[J]. Am J Respir Crit Care Med 2019,159(2):468-472.

[8] Marttin DJ, Schoub BD, Miller GB, et al. AIDS and tuberculosis [J]. S Afr Med J, 2020,78(2126):533-535.

[9] Heym B, Honore N, Ruffot-Pernot C, et al. Implications of multidrug resistance for future of short-course chemotherapy of tuberculosis;a molecular study[J]. Lancet, 2017, 344(39): 293-298.

[10] 王芙蓉,高飞. 13例利福平耐药结核病患者采用标准方案治疗的效果分析[J]. 结核病与肺部健康杂志,2017,6(1):82-84.

[11] 罗丹,蓝如东,林玫. 耐药结核病发生机制研究进展[J]. 应用预防医学,2017,23(5):436-438.

[12] Ramaswamy S, Musser JM. Molecular genetic basis of antimicrobial agent resistance in *Mycobacterium tuberculosis*[J]. Tuber Lung Dis, 2018,79(1):23-29.

[13] 马小华,万智敏,向延根,等. 结核分枝杆菌耐药基因突变位点对异烟肼体外最小抑菌浓度的影响[J]. 广西医学,2017,39(3):322-325.

[14] Honore N, Marchal G, Cole ST. Novel mutation in 16S rRNA associated with streptomycin dependence in *Mycobacterium tuberculosis* [J]. Antimicrob Agents Chemother, 2015, 39(3): 769-770.

[15] Telenti A, Philipp WJ, Sreevatsan S, et al. The emb operon, a gene cluster of *Mycobacterium tuberculosis* involved in resistance to ethambutol [J]. Nat Med, 2017, 3(5):567-570.

[16] 邓章莉,吴道深,李彦良,等. 110例耐药肺结核病临床特征分析[J]. 结核病与肺部健康杂志,2015,4(2):113-115.

[17] Helen M. Insights and challenges in tuberculosis vaccine development[J]. Lancet Respir Med,2019,7(9):810-819.

[18] Enriquez AB, Izzo A, Miller SM, et al. Advancing adjuvants for *Mycobacterium tuberculosis* therapeutics [J]. Front Immunol, 2021,12(1):740117.

[19] Kumarasamy N, Poongulali S, Beulahet FE, et al. Long-term safety and immunogenicity of the M72/AS01E candidate tuberculosis vaccine in HIV-positive and-negative Indian adults; results from a phase II randomized controlled trial[J]. Medicine (Baltimore), 2018,97(45):13120.

[20] 徐海丽,俊杰,刘红梅,等. 结核疫苗及免疫策略研究进展[J]. 中国感染与化疗杂志,2023,23(5):659-666.

[21] Xing Z, Mcfarland CT, Sallenave JM, et al. Intranasal mucosal boosting with an adenovirus-vectored vaccine markedly enhances the protection of BCG-primed guinea pigs against pulmonary tuberculosis [J]. PLoS One, 2009, 4(6):5856.

[22] 周方斌,张逸龙,张冬梅. 国内外结核病临床在研疫苗最新研究进展[J]. 中国血吸虫病防治杂志,2024,36(2):201-206,218.

[23] Cotton MF, Madhi SA, Luabeya AK, et al. Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies;a phase II randomized controlled trial[J]. Pediatr Infect Dis J, 2024,33(7):812-818.

[24] Nell AS, D'lom E, Bouic P, et al. Safety, tolerability, and immunogenicity of the novel antituberculous vaccine RUTI; randomized, placebo-controlled phase II clinical trial in patients with latent tuberculosis infection [J]. PLoS One, 2020, 9(2): 89612.

[25] Sharma SK, Katoch KM Sarin R, et al. Efficacy and safety of *Mycobacterium indicus* parni as an adjunct therapy in category II pulmonary tuberculosis in a randomized trial [J]. Sci Rep, 2017,7(1):3354.

【收稿日期】 2024-09-19 【修回日期】 2024-12-09

(上接 266 页)

[44] Li XV, Leonardi I, Putzel GG, et al. Immune regulation by fungal strain diversity in inflammatory bowel disease[J]. Nature, 2022, 603(7902):672-678.

[45] Wang S, Yin F, Sun W, et al. The causal relationship between gut microbiota and nine infectious diseases; a two-sample Mendelian randomization analysis[J]. Front Immunol, 2024, 15:1304973.

[46] Li C, Li Y, Wang N, et al. Comprehensive modulatory effects of whole grain consumption on immune-mediated inflammation in middle-aged and elderly community residents: A real-world randomized controlled trial[J]. Redox Biol, 2024, 76:103337.

[47] Khan MT, Nieuwdorp M, Backhed F. Microbial modulation of insulin sensitivity[J]. Cell Metab, 2014, 20(5):753-760.

[48] Saha B, A T R, Adhikary S, et al. Exploring the relationship between diet, lifestyle and gut microbiome in colorectal cancer development; a recent update[J]. Nutr Cancer, 2024, 76(9):789-814.

[49] Iqbal Z, Ahmed S, Tabassum N, et al. Role of probiotics in prevention and treatment of enteric infections; a comprehensive review[J]. Biotech, 2021, 11(5):242.

[50] Cheng F, Huang Z, Li Z, et al. Efficacy and safety of fecal microbiota transplant for recurrent *Clostridium difficile* infection in inflammatory bowel disease; a systematic review and meta-analysis[J]. Rev Esp Enferm Dig, 2022, 114(9):543-549.

[51] Gangwani MK, Aziz M, Aziz A, et al. Fresh versus frozen versus lyophilized fecal microbiota transplant for recurrent clostridium difficile infection; a systematic review and network meta-analysis [J]. J Clin Gastroenterol, 2023, 57(3):239-245.

[52] Mcdonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for clostridium difficile infection in adults and children: 2017 update by the infectious diseases society of america (idsa) and society for healthcare epidemiology of america (SHEA) [J]. Clin Infect Dis, 2018, 66(7):e1-e48.

[53] Yeshe K, Jamtsho T, Wangchuk P. Current Treatments, emerging therapeutics, and natural remedies for inflammatory bowel disease[J]. Molecules, 2024, 29(16):3954.

【收稿日期】 2024-09-18 【修回日期】 2024-12-15